Document is current
Any future updates will be listed below
-
Authors
Reuter, Uwe
Lucas, Christian
Dolezil, David
Hand, Austin L.
Port, Martha D.
Nichols, Russell M.
Stroud, Chad
Tockhorn-Heidenreich, Antje
Detke, Holland C. https://orcid.org/0000-0002-1316-6064
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03559257 at ClinicalTrials.govDocuments that mention this clinical trial
Benefit–Risk Assessment of Galcanezumab Versus Placebo for the Treatment of Episodic and Chronic Migraine Using the Metrics of Number Needed to Treat and Number Needed to Harm
https://doi.org/10.1007/s12325-021-01848-x
Effect of Galcanezumab on Total Pain Burden in Patients Who Had Previously Not Benefited from Migraine Preventive Medication (CONQUER Trial): A Post Hoc Analysis
https://doi.org/10.1007/s12325-022-02233-y
Effects of Galcanezumab on Health-Related Quality of Life and Disability in Patients with Previous Failure of 2–4 Migraine Preventive Medication Categories: Results from a Phase IIIb Randomized, Placebo-Controlled, Multicenter Clinical Trial (CONQUER)
https://doi.org/10.1007/s40261-021-01115-5
Galcanezumab in Patients with Multiple Previous Migraine Preventive Medication Category Failures: Results from the Open-Label Period of the CONQUER Trial
https://doi.org/10.1007/s12325-021-01911-7
-
Funding
Funding for this research was provided by:
Eli Lilly and Company
- License Information
-
More Information
Article History
Received: 28 June 2021
Accepted: 31 August 2021
First Online: 20 September 2021
